我们在此报告了在硅烷存在下用脂肪族叠氮化物对未活化烯烃进行有效且高度非对映选择性的分子间抗马尔科夫尼科夫加氢胺化。该系统可耐受多种叠氮化物和烯烃,并使用烯烃作为限制试剂。机理研究表明,自由基链途径包括胺自由基的形成、烯烃的自由基加成和从硅烷到 β-胺烷基自由基的 HAT。建议使用空间大的硅烷有助于 HAT 具有出色的非对映选择性。计算分析揭示了脂肪族叠氮化物与甲硅烷基自由基活化形成胺基自由基的反应途径。
Ruthenium-Catalyzed <i>para</i>
-Selective C−H Alkylation of Aniline Derivatives
作者:Jamie A. Leitch、Claire L. McMullin、Andrew J. Paterson、Mary F. Mahon、Yunas Bhonoah、Christopher G. Frost
DOI:10.1002/anie.201708961
日期:2017.11.20
The para‐selectiveC−H alkylation of aniline derivatives furnished with a pyrimidine auxiliary is herein reported. This reaction is proposed to take place via an N−H‐activated cyclometalate formed in situ. Experimental and DFT mechanistic studies elucidate a dual role of the ruthenium catalyst. Here the ruthenium catalyst can undergo cyclometalation by N−H metalation (as opposed to C−H metalation in
is one of the most attractive catalysts, especially for aromatic C–H functionalizations. However, stoichiometric amounts of oxidants and strong carbanions are required, and C–H tertiary alkylation, especially with electron-deficient alkylgroups, is unexplored. In this paper, we describe the development of iron-catalyzed selective C–H tertiary alkylations with heteroaromatics, in which an iron salt
[EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2015005901A1
公开(公告)日:2015-01-15
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
Ruthenium catalyzed remote C4-selective C–H functionalisation of carbazoles <i>via</i> σ-activation
作者:Jamie A. Leitch、Callum J. Heron、Janette McKnight、Gabriele Kociok-Köhn、Yunas Bhonoah、Christopher G. Frost
DOI:10.1039/c7cc07606a
日期:——
We report the C4-selective C–H alkylation of carbazole derivatives furnished with a pyrimidine directing group at N9. This was realized using ruthenium catalyzed σ-activation methodology, whereby C–H activation at C1 enables the interaction of this ruthenacycle, at the para position to the metal center, with tertiary alkyl radicals.
The present invention provides a novel piperidine derivative and a tachykinin receptor antagonist containing same, as well as a compound represented by the formula:
wherein R
1
is carbamoylmethyl, methylsulfonylethylcarbonyl and the like; R
2
is methyl or cyclopropyl; R
3
is a hydrogen atom or methyl; R
4
is a chlorine atom or trifluoromethyl; R
5
is a chlorine atom or trifluoromethyl; and a group represented by the formula:
is a group represented by the formula:
wherein R
6
is a hydrogen atom, methyl, ethyl or isopropyl; R
7
is a hydrogen atom, methyl or a chlorine atom; and R
8
is a hydrogen atom, a fluorine atom, a chlorine atom or methyl; or 3-methylthiophen-2-yl, and a salt thereof.